Daniel Tassé

Daniel Tassé currently works at DBV Technologies SA, as Chief Executive Officer & Director from 2019, BioQ Pharma, Inc., as Director from 2014, REGENXBIO, Inc., as Lead Independent Non-Executive Director from 2024, and Roundtable On Critical Care Policy, as Director.
Mr. Tassé also formerly worked at Ikaria, Inc., as Chairman, President & Chief Executive Officer from 2009 to 2015, Alcresta Therapeutics, Inc., as Chairman & Chief Executive Officer from 2016 to 2018, Biotechnology Innovation Organization, as Director from 2011 to 2015, Bellerophon Therapeutics, Inc., as Director from 2014 to 2019, Indivior PLC, as Senior Independent Director from 2020 to 2021, GSK Plc, as Vice President & Regional Director-Australasia in 2004, Pharmaceutical Research & Manufacturers of America, as Director from 2011 to 2015, HLS Therapeutics, Inc., as Independent Director from 2018 to 2019, Baxter International, Inc., as GM-Pharmaceuticals & Technologies Business Unit in 2008, Healthcare Leadership Council, as Member, and NRG Energy Ltd., as Chief Financial Officer.
Mr. Tassé received his undergraduate degree from the University of Montréal.